NSE · MOLBIO
Molbio Diagnostics Limited
Historical price visualisation is temporarily undergoing corporate data-licensing maintenance. Full interactive price and chart data will return following our upcoming authorized NSE/BSE data-feed deployment. Derived metrics (valuation ratios, market-cap rank), company financials, shareholding, corporate actions, and mutual-fund holdings remain available.
Market cap rank
#403
of 5,018 stocks
▲ 871W
Peak #401 · 02 Oct 2026
Operating in Healthcare, Molbio Diagnostics Limited carries a steep earnings multiple that prices in strong future growth, is growing revenue rapidly, and earns a healthy return on equity.
Market Cap
17,061.72 Cr
P/E Ratio
104.67
P/B Ratio
14.91
ROE
14.25%
ROCE
16.50%
Dividend Yield
—
52W High
—
52W Low
—
Quarterly financials
| Metric | Q1 2026-27 |
|---|---|
| Revenue | 408.38 Cr |
| Net Profit | 52.74 Cr |
| EPS | 5.21 |
| Operating Profit | 86.61 Cr |
Shareholding pattern
Promoter
41.29%
Public
58.71%
PUBLIC BREAKDOWN
FII
1.51%
DII
16.37%
MF (within DII)
2.25%
Individuals
29.39%
Mutual fund holdings
₹673.84
Cr total
28
Schemes
10
Fund Houses
₹673.84 Cr
Total Exposure
Kotak Mahindra Mutual Fund₹278.54 Cr (41.3%)
HDFC Mutual Fund₹115.03 Cr (17.1%)
Mirae Asset Mutual Fund₹114.46 Cr (17.0%)
Nippon India Mutual Fund₹59.83 Cr (8.9%)
ICICI Prudential Mutual Fund₹36.35 Cr (5.4%)
Others₹69.64 Cr (10.3%)
Recent corporate actions
No corporate actions on record for this stock.
Need this data in your app?
Full price history, technical indicators, and every field above via one REST API call.